Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.

About Ambit
Board of Directors
Clinical Advisory Board – Hematology/Oncology
Directions to Ambit Biosciences Corporate Headquarters
Management Team
Our Strategy
Scientific Advisors
Ambit Biosciences Corporation
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
Astellas Pharma Inc
Benefits
Careers
Clinical Trials
Contact Us
Events
Investors
KINOMEscan – High-Throughput Kinase Selectivity Profiling
News
Opportunities
Partners
Strategic Partnerships
Teva
Presentations
Privacy Policy
Product Pipeline
About quizartinib
AC220 – A Best-In-Class FLT-3 Inhibitor for AML
AC410
AC708
AURORA Kinase
BRAF Kinase
CEP-32496 Development
Scientific Publications & Presentations
Publications
Recruiters
Skilled. Resourceful. Validated.
Terms of Use

Ambit is currently in product development of the following:

From profiling services to clinical development expertise, find out what Ambit has to offer.